Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Enhertu has been recommended for approval by the CHMP for patients with previously treated HER2-positive metastatic solid tumours.
Therapeutic Area
Therapeutic area intelligence for HER2-positive solid tumours with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.